A28 Therapeutics

A28 Therapeutics is a clinical-stage biopharmaceutical company developing a targeted oncolytic peptide (“TOP”) platform for the treatment of multiple cancer types. Our initial focus is on Stage IV ovarian cancer with liver metastasis and primary liver cancer, indications with significant unmet medical need, large global markets, and where we have multiple potential near-term value-creating milestones, data readouts, and licensing/exit opportunities.